172 related articles for article (PubMed ID: 21127944)
21. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
22. Establishment and validation of real-time polymerase chain reaction method for CDH1 promoter methylation.
Toyooka KO; Toyooka S; Maitra A; Feng Q; Kiviat NC; Smith A; Minna JD; Ashfaq R; Gazdar AF
Am J Pathol; 2002 Aug; 161(2):629-34. PubMed ID: 12163387
[TBL] [Abstract][Full Text] [Related]
23. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
Castelo-Branco P; Choufani S; Mack S; Gallagher D; Zhang C; Lipman T; Zhukova N; Walker EJ; Martin D; Merino D; Wasserman JD; Elizabeth C; Alon N; Zhang L; Hovestadt V; Kool M; Jones DT; Zadeh G; Croul S; Hawkins C; Hitzler J; Wang JC; Baruchel S; Dirks PB; Malkin D; Pfister S; Taylor MD; Weksberg R; Tabori U
Lancet Oncol; 2013 May; 14(6):534-42. PubMed ID: 23598174
[TBL] [Abstract][Full Text] [Related]
24. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma.
Yu J; Zhang H; Gu J; Lin S; Li J; Lu W; Wang Y; Zhu J
BMC Cancer; 2004 Sep; 4():65. PubMed ID: 15367334
[TBL] [Abstract][Full Text] [Related]
25. Reduced levels of E-cadherin correlate with progression of corticotroph pituitary tumours.
Evang JA; Berg JP; Casar-Borota O; Lekva T; Kringen MK; Ramm-Pettersen J; Bollerslev J
Clin Endocrinol (Oxf); 2011 Dec; 75(6):811-8. PubMed ID: 21595730
[TBL] [Abstract][Full Text] [Related]
26. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer.
Corso G; Carvalho J; Marrelli D; Vindigni C; Carvalho B; Seruca R; Roviello F; Oliveira C
J Clin Oncol; 2013 Mar; 31(7):868-75. PubMed ID: 23341533
[TBL] [Abstract][Full Text] [Related]
27. Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer.
Graziano F; Arduini F; Ruzzo A; Bearzi I; Humar B; More H; Silva R; Muretto P; Guilford P; Testa E; Mari D; Magnani M; Cascinu S
Clin Cancer Res; 2004 Apr; 10(8):2784-9. PubMed ID: 15102685
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of E-cadherin and N-cadherin expression in Gliomas.
Noh MG; Oh SJ; Ahn EJ; Kim YJ; Jung TY; Jung S; Kim KK; Lee JH; Lee KH; Moon KS
BMC Cancer; 2017 Aug; 17(1):583. PubMed ID: 28851312
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer.
Barber M; Murrell A; Ito Y; Maia AT; Hyland S; Oliveira C; Save V; Carneiro F; Paterson AL; Grehan N; Dwerryhouse S; Lao-Sirieix P; Caldas C; Fitzgerald RC
J Pathol; 2008 Nov; 216(3):295-306. PubMed ID: 18788075
[TBL] [Abstract][Full Text] [Related]
30. Disordered beta-catenin expression and E-cadherin/CDH1 promoter methylation in gastric carcinoma.
Wang L; Zhang F; Wu PP; Jiang XC; Zheng L; Yu YY
World J Gastroenterol; 2006 Jul; 12(26):4228-31. PubMed ID: 16830381
[TBL] [Abstract][Full Text] [Related]
31. Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival.
Korkolopoulou P; Kouzelis K; Christodoulou P; Papanikolaou A; Thomas-Tsagli E
Acta Neuropathol; 1998 Jun; 95(6):617-24. PubMed ID: 9650754
[TBL] [Abstract][Full Text] [Related]
32. Aberrant Methylation of the E-Cadherin Gene Promoter Region in the Endometrium of Women With Uterine Fibroids.
Li Y; Ran R; Guan Y; Zhu X; Kang S
Reprod Sci; 2016 Aug; 23(8):1096-102. PubMed ID: 26880767
[TBL] [Abstract][Full Text] [Related]
33. Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer.
Wheeler JM; Kim HC; Efstathiou JA; Ilyas M; Mortensen NJ; Bodmer WF
Gut; 2001 Mar; 48(3):367-71. PubMed ID: 11171827
[TBL] [Abstract][Full Text] [Related]
34. Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors.
Kuo LT; Kuo KT; Lee MJ; Wei CC; Scaravilli F; Tsai JC; Tseng HM; Kuo MF; Tu YK
Int J Cancer; 2009 Jun; 124(12):2872-9. PubMed ID: 19330828
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
Wu X; Wu F; Xu D; Zhang T
J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
[TBL] [Abstract][Full Text] [Related]
36. Aberrant promoter methylation and expression of the imprinted PEG3 gene in glioma.
Otsuka S; Maegawa S; Takamura A; Kamitani H; Watanabe T; Oshimura M; Nanba E
Proc Jpn Acad Ser B Phys Biol Sci; 2009; 85(4):157-65. PubMed ID: 19367087
[TBL] [Abstract][Full Text] [Related]
37. Promoter hypermethylation may contribute to E‑cadherin repression in the human salivary carcinoma ex pleomorphic adenoma.
Xia L; Hu Y; Gu T; Wang L; Tian Z
Int J Oncol; 2018 Feb; 52(2):496-504. PubMed ID: 29207084
[TBL] [Abstract][Full Text] [Related]
38. Aberrant hypermethylation of non-promoter zygote arrest 1 (ZAR1) in human brain tumors.
Watanabe T; Yachi K; Ohta T; Fukushima T; Yoshino A; Katayama Y; Shinojima Y; Terui T; Nagase H
Neurol Med Chir (Tokyo); 2010; 50(12):1062-9. PubMed ID: 21206179
[TBL] [Abstract][Full Text] [Related]
39. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
40. An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity.
Nguyen A; Legrain M; Noel G; Coca A; Meyer Ea N; Schott R; Lasthaus C; Chenard MP; Gaub MP; Lessinger JM; Guenot D; Entz-Werle N
Curr Cancer Drug Targets; 2015; 15(7):624-40. PubMed ID: 26118907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
